Research programme: prostaglandin D2 receptor antagonists - Atopix Therapeutics

Drug Profile

Research programme: prostaglandin D2 receptor antagonists - Atopix Therapeutics

Alternative Names: ATX2286

Latest Information Update: 18 Dec 2014

Price : $50

At a glance

  • Originator Oxagen
  • Class Small molecules
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma; Hypersensitivity; Inflammation; Respiratory tract disorders

Most Recent Events

  • 18 Dec 2014 Atopix Therapeutics plans a phase I trial in Healthy volunteers in the United Kingdom (NCT02316912)
  • 31 Oct 2012 Prostaglandin D2 receptor antagonist research programme licensed to Atopix Therapeutics worldwide
  • 31 May 2009 Preclinical trials in Respiratory tract disorders in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top